Towards estimating true cholera burden: a systematic review and meta-

analysis of _Vibrio cholerae_ positivity

Running title: Estimating _Vibrio cholerae_ positivity

Kirsten E. Wiens[1,2], Hanmeng Xu[1], Kaiyue Zou[1], John Mwaba[3,4], Justin Lessler[1,5,6], Espoir B.

Malembaka[1,7], Maya N. Demby[1], Godfrey Bwire[8], Firdausi Qadri[9], Elizabeth C. Lee[1], Andrew S.

Azman[1]

[1] Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Johns

Hopkins University, Baltimore, USA

[2] Department of Epidemiology and Biostatistics, College of Public Health, Temple University,

Philadelphia, USA

[3] Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia

[4] Department of Biomedical Sciences, School of Health Sciences, University of Zambia, Lusaka,

Zambia

[5] Department of Epidemiology, Gillings School of Global Public Health, University of North

Carolina at Chapel Hill, Chapel Hill, USA

[6] Carolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, USA

[7] Center for Tropical Diseases and Global Health (CTDGH), Université Catholique de Bukavu,

Bukavu, Democratic Republic of the Congo

[8] Division of Public Health Emergency Preparedness and Response, Ministry of Health,

Kampala, Uganda

[9] Infectious Diseases Division, International Centre for Diarrhoeal Disease Research

Bangladesh (icddr,b), Dhaka, Bangladesh

Corresponding author

Andrew S. Azman, PhD

Associate Scientist

Department of Epidemiology

Johns Hopkins Bloomberg School of Public Health

615 N. Wolfe Street

Baltimore, MD 21205

azman@jhu.edu

Alternative corresponding author

Kirsten E. Wiens, PhD

Assistant Professor

Department of Epidemiology and Biostatistics

Temple University College of Public Health

1301 Cecil B. Moore Avenue, Ritter Annex 911

Philadelphia, PA 19122

kirsten.wiens@temple.edu

Key points

By pooling results from 113 studies and adjusting for diagnostic tests and study methods, we find

that approximately half of suspected cholera cases represent true *Vibrio cholerae* infections, though

this fraction varies widely across epidemiological settings.

Keywords

cholera, *Vibrio cholerae*, diagnostic test, suspected cholera, confirmed cholera

Abstract

<u>Background</u>: Cholera surveillance relies on clinical diagnosis of acute watery diarrhea.

Suspected cholera case definitions have high sensitivity but low specificity, challenging our

ability to characterize cholera burden and epidemiology. Our objective was to estimate the

proportion of clinically suspected cholera that are true *Vibrio cholerae* infections and identify

factors that explain variation in positivity.

<u>Methods</u>: We conducted a systematic review of studies from 2000-2021 that tested ≥10

suspected cholera cases for *V. cholerae* O1/O139 using culture, PCR and/or a rapid diagnostic

test. We estimated diagnostic test sensitivity and specificity using a latent class meta-analysis.

We estimated positivity using a random-effects meta-analysis, adjusting for test performance

and study methodology.

<u>Results</u>: We included 113 studies from 28 countries. *V. cholerae* positivity was lower in studies

with representative sampling and lower minimum ages in suspected case definitions. After

adjusting for sampling methods, case definitions, and tests, on average half (49%, 95% Credible

Interval: 43%-54%) of suspected cases represented true *V. cholerae* infections, although

variation across studies was high. Odds of a suspected case having a true infection were 1.64

(95% Credible Interval: 1.06-2.52) times higher when surveillance was initiated in response to

an outbreak than in non-outbreak settings.

<u>Conclusions</u>: Burden estimates based on suspected cases alone may overestimate the

incidence of medically attended cholera about twofold. However, accounting for cases missed

by traditional clinical surveillance is key to unbiased overall cholera burden estimates. Given

variability between settings, assumptions about positivity, which are necessary without

exhaustive testing, should be based on local data.

Introduction

Current estimates of cholera burden rely on clinical diagnosis of individuals with acute watery diarrhea (i.e., suspected cholera cases) [1,2]. It is unclear how many *Vibrio cholerae* O1/O139 (serogroups that cause current epidemics) infections get missed due to mild symptoms and other barriers to care-seeking or how many get overcounted due to non-specific suspected case definitions. In Bangladesh, previous studies estimated that asymptomatic and unreported infections account for at least half of *V. cholerae* infections [3–5]. Meanwhile, the proportion of suspected cholera cases that represent laboratory-confirmed infections varies widely between studies, from 6% of those tested during routine surveillance in Bangladesh [6] to 72% of those tested during the initial phase of the 2017 outbreak in Yemen [7].

This wide variation in positivity may be caused by differences between sites in *V. cholerae* epidemiology [8], epidemiology of non-cholera diseases causing the same clinical symptoms [9–12], and variations in diagnostic tests and case definitions [13–15]. Typical suspected cholera case definitions have been shown to have high sensitivity but low specificity [14] and can vary by location across seasons [13]. Culture-based methods or PCR are the gold standards to confirm cholera in clinical samples and generally have high specificity. Lateral flow rapid diagnostic tests (RDT) may also be used and can be as sensitive as PCR [16]. Although recommended by the Global Task Force on Cholera Control (GTFCC) [17], systematic microbiological confirmation in surveillance is not always implemented, particularly during outbreaks when resources are limited [8].

Understanding *V. cholerae* positivity among clinical cases could provide insights needed to improve laboratory testing strategies and allow for better estimates of cholera burden and risk, which are often used to allocate cholera resources, including oral cholera vaccines. We sought to address this knowledge gap by modeling the relationship between clinically suspected and laboratory confirmed cholera. Specifically, we aimed to estimate the proportion of

suspected cholera cases that represent true *V. cholerae* O1/O139 infections and identify factors

that explain variability in positivity across sites.

Methods

<u>Terminology</u>

We focused on *V. cholerae* O1 and O139 because these are the serogroups that are

responsible for the current 7th pandemic and the only ones known to lead to large outbreaks in

humans [18]. These are also the serogroups that are targeted by each of the commonly used *V.*

cholerae diagnostic tests (culture, PCR, RDT). Throughout this manuscript, we refer to the

proportion of suspected cholera cases that represent true *V. cholerae* O1/O139 infections as "*V.*

cholerae positivity" or "cholera positivity". In addition, since the available data did not allow us to

evaluate performance of multiple RDTs, we refer to RDT as any rapid diagnostic test for *V.*

cholerae O1/O139 and do not distinguishing between different RDT manufacturers or whether

the RDT is enriched/direct swab RDT or stool RDT.

<u>Systematic review</u>

We searched PubMed, Embase, Scopus, Google Scholar and *medRxiv* on October 16,

2021 using search provided in the Supplementary Methods. We included studies that: 1)

collected human samples, 2) reported the number of suspected and confirmed cholera cases in

the sampling frame, 3) used culture, PCR, and/or RDT to test suspected cases for cholera, and

4) had at least one suspected case sample collected on or after January 1, 2000. We excluded

studies that: 1) used a case definition not specific for suspected cholera (i.e., we accepted non-

bloody watery diarrhea, acute watery diarrhea, or simply suspected cholera but not diarrhea,

acute diarrhea, or acute gastroenteritis), 2) sampled only special populations (i.e., people living

with HIV or cancer), 3) selected suspected cases based on epidemiological link to other cases

or environmental sources, 4) tested fewer than 10 suspected cases, 5) were reported in

languages other than English, French, Spanish, and Chinese.

Titles, abstracts, and full texts were uploaded to Covidence, a web-based screening tool

(https://www.covidence.org/), and were assessed independently by two of the reviewers (ASA,

ECL, HX, KEW, KZ, MND) for inclusion. Conflicts were resolved either by a third reviewer or

through consensus/discussion. Data were extracted from included studies in a shared

spreadsheet (Supplementary Data 1). The key extracted items included study timeframe and

location, surveillance type (routine, outbreak, post-vaccination, or hybrid), case definition of

suspected cholera (including age constraint and whether dehydrated or hospitalized, if

provided), test method(s), sampling strategy for the test (all suspected cases, systematic or

random sampling, convenience sampling, or unreported), number of tested and confirmed

suspected cases, among other sample characteristics, if included. If the surveillance contained

multiple timeframes, tested samples with multiple tests, or reported stratified results, we

extracted the data separately into different rows in the spreadsheet.

To identify overlapping samples, we manually reviewed all studies with overlapping

timeframes by country. We excluded studies that had shorter timeframes, fewer suspected

cases tested, less representative sampling methods, fewer confirmation tests, or reported

positive results by two tests but did not disaggregate. Within studies, when suspected and

confirmed cases were stratified multiple ways, we included the stratification by surveillance type

if available, followed by age, antibiotic use, dehydration status, year, geography, or sex, in that

order. When studies used multiple RDTs, we included results for Crystal VC (Arkray Healthcare

Pvt. Ltd, Gujarat, India) and direct rapid tests (as opposed to rapid tests performed after an

enrichment step) because these were the most common.

<u>Data analysis</u>

Estimating sensitivity and specificity of cholera confirmation tests

We constructed a latent-class model to assess sensitivity and specificity of culture, PCR,

and RDT, assuming none had perfect performance. We fit a hierarchical conditional

dependence model, similar to that proposed by Wang *et al.*, which takes into account potential

pairwise dependence between the tests that could occur if the tests have reduced performance

for similar reasons [19]. We performed inference in a Bayesian framework using Just Another

Gibbs Sampler (JAGS) through the rjags package in R [20,21]. We pooled estimates across four

published studies that reported cholera confirmation results for all three test methods [16,22–

24]. We used uninformative prior distributions on sensitivity and specificity of each test with a

lower bound set based on plausible values from the literature (Table S1). We ran 4 chains of

100,000 iterations and assessed convergence using the Gelman-Rubin R-hat statistic.

Estimating V. cholerae *positivity and sources of heterogeneity*

We pooled estimates of *V. cholerae* positivity across all studies using a meta-analysis

with hierarchical modeling, adjusting for sensitivity and specificity of the diagnostic tests as well

as study methodology and setting (see Supplementary Methods for the full statistical model).

We used the same statistical model to examine factors associated with variation in positivity.

To examine between- versus within-study heterogeneity, we calculated the I^2 statistic

[25] with

$$I^2 = \frac{\tau^2}{\tau^2 + v}$$

where τ^2 was between-study heterogeneity or $\sigma_{logit(p_{pos})}$ following [26]. We calculated the

within-study variance, v, [27] as:

$$v = \frac{(k-1)\sum_1^i \omega_i}{(\sum_1^i \omega_i)^2 - \sum_1^i \omega_i^2}$$

where k was the number of studies or observations included in the meta-analysis, and $\omega_i =$

$1/v_i$ where v_i was the variance of the proportion positive by culture, PCR or RDT within each

study/observation. When multiple tests were used in a study, we used the maximum variance

estimate across the tests.

Data availability

All input data and analytical code are available at

https://github.com/HopkinsIDD/cholera_positivity. This study was approved by the Johns

Hopkins University Institutional Review Board and Temple University Institutional Review Board.

Results

<u>Study characteristics</u>

We identified 125 studies that met our inclusion criteria (Figure 1). Of these, 113 studies

contained non-overlapping samples and were included in our analysis dataset (Figure 1). The

non-overlapping data came from 28 countries and were reported at different geographic levels,

including the country level (n=38 study locations) and first (n=57), second (n=76), and third

administrative levels (n=34) (Figure S1). Data were from 1992 through 2019 with most data

coming from 2015—2019 (n=67 study-periods), followed by 2010—2014 (n=45), 2005—2009

(n=32), and 1997—2004 (n=29) (Figure S2). Most studies were conducted in South Asia and

West, Central, and East Africa, with additional studies from Haiti, Yemen, Iraq, Iran, Laos,

Vietnam, Papua New Guinea, and the Philippines (Figure S1).

Most of the data were from surveillance studies (77%), followed by diagnostic test

accuracy studies (15%) and vaccine effectiveness studies (7%) (Table 1). Thirty percent used

high-quality sampling methods (i.e., tested all suspected cases, a random sample, or

systematically selected every nth suspected case), while the remaining 70% used convenience

sampling or did not report the sampling approach (Table 1). Even though most studies did not

include *V. cholerae* positivity disaggregated by individual-level characteristics, 28% reported the

proportion of suspected cases under age five, 8% reported the proportion severely dehydrated,

8% reported the proportion on antibiotics, and one study reported all three (Table S2).

V. cholerae positivity in unadjusted data

We found that reported *V. cholerae* positivity varied by study methodology. Median

positivity was 36% by culture, 37% by PCR, and 56% by RDT, with substantial overlap between

distributions (Figure 2A). Positivity was higher across studies that used low quality or

convenience sampling methods (40%) compared to those that used high quality or

representative sampling (33%) (Figure 2B). Positivity increased with higher minimum ages in

suspected cholera case definitions (Figure 2C), and we found a modest negative correlation

between positivity and proportion of suspected cases under age five (Spearman r = -0.51; 95%

Confidence Interval: -0.72 to -0.21) (Figure S3A).

Unadjusted positivity was higher when surveillance was initiated in response to an

outbreak (median of 45%) compared to situations where surveillance was routine or post-

vaccination (median of 35%) (Figure 2D). We found limited evidence for differences by mean

annual suspected case incidence rate in countries where these estimates were available (Figure

S3B), though this result should be interpreted with caution because incidence rates are for

2010-2016 [2] which is not the same timeframe as each study.

We found a modest positive correlation between positivity and the proportion of

suspected cases severely dehydrated (Spearman r = 0.52; 95% CI: 0.01 to 0.90) (Figure S3C).

While not statistically significant, we found a weak negative correlation between positivity and

the proportion of suspected cases that had received antibiotics prior to testing (Spearman r = -

0.46; 95% CI: -0.84 to 0.13) (Figure S3D).

Adjusted underlying *V. cholerae* positivity

Since different imperfect diagnostic tests were used to confirm *V. cholerae* O1/O139, we

adjusted positivity estimates from each study to account for test performance. To estimate the

average performance of each type of diagnostic test, we pooled estimates of sensitivity and

specificity across four studies that reported detailed results for all three tests (see Methods).

This included data from Bangladesh [24], South Sudan [16], Kenya [22], and Zambia [23]. We

estimated an average sensitivity of 82.0% (95% Credible Interval: 37.5-98.7) and specificity of

94.3% (95% CI: 81.5-99.6) for culture, an average sensitivity of 85.1% (95% CI: 53.6%-98.9%)

and specificity of 94.2 (95% CI: 81.8-99.7) for PCR, and an average sensitivity of 90.4% (95%

CI: 55.2-99.5) and specificity of 88.9% (95% CI: 54.9-99.4) for RDT (Figure 3A, Table S3).

After adjusting for diagnostic test performance (see Methods), we estimated that 49%

(95% Credible Interval: 43%-54%) of suspected cases tested were true *V. cholerae* O1/O139

infections (Figure 3, Figure S4, Table S4). This estimate remained constant after additionally

adjusting for differences in study methods (i.e., sampling quality and age minimum in case

definition) and outbreak setting (Figure 3, Table S4), as well as in sensitivity analysis where we

increased variance on all prior distributions (see Methods) (Table S4).

We found substantial heterogeneity between studies (I^2 = 99.99; τ^2 = 0.79) (Figure 4).

When we used the model to predict positivity for a hypothetical new study site (i.e., posterior

predictive distribution), median positivity remained similar but, as expected, uncertainty was

much higher (48%, 95% CI: 7.1%-92%) (Figure S4).

Factors associated with variation in *V. cholerae* positivity

We then examined factors that could explain variation in *V. cholerae* positivity. After

adjusting for test performance, sampling quality, and outbreak setting, we found that each 1-

year increase in the minimum age in the case definition was associated with 1.16 (95% CI: 1.01-

1.34) times higher odds of a suspected cholera case having a true infection (Table S5). The

highest minimum age set was 10, which was used in a single study (Figure 2C). We observed a

similar trend when we analyzed minimum age in case definition as a categorical rather than

continuous variable, though the increases in odds of positivity by age in definition were not

significant and had high uncertainty (Table S6).

We estimated that the odds of a suspected cholera case having a true *Vibrio cholerae*

O1/O139 infection were 1.64 (95% CI: 1.06-2.52) times higher when surveillance was initiated in

response to a cholera outbreak compared to non-outbreak surveillance, after adjusting for test

performance, sampling quality, and case definition (Table S5). These estimates remained

consistent across sensitivity analyses (Table S7).

Discussion

Here we estimated that on average half of medically attended suspected cholera cases

represent true *V. cholerae* O1/O139 infections. We found that *V. cholerae* positivity was higher

when higher ages were set in case definitions and when surveillance was initiated in response

to an outbreak. Additionally, we found substantial heterogeneity in *V. cholerae* positivity

between studies, so that simply dividing suspected cholera case counts by two to estimate the

true number of cases will not be appropriate in all settings.

These findings have several implications for cholera surveillance policy. The GTFCC

defines suspected cholera in areas where an outbreak has not yet been reported as acute

watery diarrhea and severe dehydration or death in individuals two years and older [17]. Our

finding that a minimum age of two or five increases specificity for identifying a true *V. cholerae*

infection in suspected cases supports this case definition. Laboratory confirmation tests are

recommended during the early stages of an outbreak and periodically once an outbreak has

been declared, ideally a minimum of five suspected case samples tested per week per health

facility [17]. Our finding that high quality sampling also increases specificity for *V. cholerae*

suggests that systematically selecting cases to test is important for accurately evaluating

endemic cholera. We also found high variability across settings, suggesting that when

systematic testing is not possible, assumptions about positivity based on data at the location

and time where cholera control decisions are made may be key to reducing bias in estimates of

true cholera incidence.

A remaining question is why only about half of medically attended suspected cholera

cases represent true infections. It is possible that we overestimated test sensitivity and have not

fully accounted for false negatives; unfortunately, this is difficult to evaluate without a gold

standard diagnostic test. A portion of the remaining suspected cases could also be infections

with other enteric pathogens, especially those with similar transmission modes as cholera that

may have outbreaks or high levels of endemic transmission concurrently. For example, in Uvira,

Democratic Republic of the Congo, 36% of suspected cholera cases were positive for

Enterotoxigenic *Escherichia coli* and 28% for *Cryptosporidium* [10]. In rural Bangladesh, the

majority of acute watery diarrhea in children under 18 months was attributable to rotavirus, while

older children were more often infected with *V. cholerae* [12]. In Haiti, 64% of acute watery

diarrhea cases tested positive for *V. cholerae* O1, 4% for rotavirus, and <1% for Shigella and

Salmonella, though rotavirus positivity was higher among children under five [11]. Thus, the

relative contribution of non-cholera watery diarrhea varies with age distribution and other

location-specific drivers of enteric infections.

One of the limitations of this study was that we could not account for all potential drivers

of *V. cholerae* positivity, which contributed to the large heterogeneity we found between studies.

In addition, *V. cholerae* positivity may be highest in the early stages of an outbreak [7,9,28], but

we could not account for this given the temporal resolution of our dataset. However, a strength

of our approach is that we pooled estimates from studies across diverse geographies, time

periods, and epidemiological contexts. A further potential limitation is that, without a gold

standard diagnostic test, sensitivity and specificity estimates may be biased if the tests are less

sensitive and/or specific for shared reasons. The hierarchical conditional dependence model we

used accounted for this pairwise dependence and increased uncertainty around our estimates

accordingly. This approach also allowed us pool test performance estimates across studies from

four countries. Thus, to our knowledge, we adjusted our estimates for test sensitivity and

specificity using the best generic estimates available. Overall, we have high confidence in our

average estimates of *V. cholerae* positivity, despite the difficulty of accurately estimating

positivity in a new location/time without confirmation tests.

These estimates of *V. cholerae* positivity address one part of the challenge in

establishing the true burden of cholera: cases that are overcounted due to non-specific

suspected case definitions. A crucial next step will be to estimate missed cases due to care

seeking and poor clinical surveillance. This could be done in part through systematically

synthesizing data from studies of care seeking behavior for diarrheal symptoms (for example

[29,30]), including where potential cholera cases seek care (e.g., at pharmacies, traditional

healers, or hospitals). This could additionally be done through population representative surveys

and active case finding, similar to studies conducted in Haiti [31] and Tanzania [32],

respectively, which demonstrated higher mortality rates associated with cholera than had been

reported through passive surveillance.

Ultimately, a better understanding of *V. cholerae* positivity will help us move towards

estimates of true cholera incidence and mortality. Given the large amount of heterogeneity

between studies, it will be important to do this in a way that accounts for variation in *V. cholerae*

positivity between sites. Moreover, the proportion of suspected cholera cases missed because

of milder symptoms or barriers to healthcare seeking needs to be estimated and accounted for.

Such estimates will provide crucial information to guide the allocation of limited resources such

as vaccines in a way that most effectively supports cholera prevention and control.

Funding

This work was supported by the Bill and Melinda Gates Foundation [grant number

OPP1171700] and the National Institute of Allergy and Infectious Disease [grant number

AI135115-01A1].

Conflicts of Interest

336   The authors declare no conflicts of interest.

References

1.   Ali M, Nelson AR, Lopez AL, Sack DA. Updated global burden of cholera in endemic

countries. PLOS Neglected Tropical Diseases **2015**; 9:e0003832.

2.   Lessler J, Moore SM, Luquero FJ, et al. Mapping the burden of cholera in sub-Saharan

Africa and implications for control: an analysis of data across geographical scales. The

Lancet **2018**; 391:1908–1915.

3.   Azman AS, Lauer SA, Bhuiyan TR, et al. Vibrio cholerae O1 transmission in Bangladesh:

insights from a nationally representative serosurvey. The Lancet Microbe **2020**; 1:e336–

e343.

4.   Mosley WH, Benenson AS, Barui R. A serological survey for cholera antibodies in rural

East Pakistan. Bull World Health Organ **1968**; 38:327–334.

5.   Weil AA, Begum Y, Chowdhury F, et al. Bacterial shedding in household contacts of

cholera patients in Dhaka, Bangladesh. Am J Trop Med Hyg **2014**; 91:738–742.

6.   Khan AI, Rashid MM, Islam MT, et al. Epidemiology of cholera in Bangladesh: findings

from nationwide hospital-based surveillance, 2014–2018. Clinical Infectious Diseases

2020; 71:1635–1642.

7.   Camacho A, Bouhenia M, Alyusfi R, et al. Cholera epidemic in Yemen, 2016–18: an

analysis of surveillance data. The Lancet Global Health **2018**; 6:e680–e690.

8. Sauvageot D, Njanpop-Lafourcade B-M, Akilimali L, et al. Cholera incidence and mortality

in sub-Saharan African sites during multi-country surveillance. PLOS Neglected Tropical

Diseases **2016**; 10:e0004679.

9. Jameel SK, Shafek MA, Abdulmohsen AM, Mohamed NS, Naji SR, Mohammed TT. The

isolation of Vibrio cholera and other enteric bacteria with molecular characterization of

Vibrio cholera during the outbreak of Baghdad/Iraq in 2015. Advances in Microbiology

2016; 6:699–715.

10. Williams C, Cumming O, Grignard L, et al. Prevalence and diversity of enteric pathogens

among cholera treatment centre patients with acute diarrhea in Uvira, Democratic Republic

of Congo. BMC Infectious Diseases **2020**; 20:741.

11. Steenland MW, Joseph GA, Lucien MAB, et al. Laboratory-confirmed cholera and rotavirus

among patients with acute diarrhea in four hospitals in Haiti, 2012–2013. Am J Trop Med

Hyg **2013**; 89:641–646.

12. Siddique AK, Ahmed S, Iqbal A, et al. Epidemiology of rotavirus and cholera in children

aged less than five years in rural Bangladesh. J Health Popul Nutr **2011**; 29:1–8.

13. Nadri J, Sauvageot D, Njanpop-Lafourcade B-M, et al. Sensitivity, specificity, and public-

health utility of clinical case definitions based on the signs and symptoms of cholera in

Africa. The American Journal of Tropical Medicine and Hygiene **2018**; 98:1021–1030.

14. Lucien MAB, Schaad N, Steenland MW, et al. Identifying the most sensitive and specific

sign and symptom combinations for cholera: results from an analysis of laboratory-based

surveillance data from Haiti, 2012–2013. The American Journal of Tropical Medicine and

Hygiene **2015**; 92:758–764.

15.   Muzembo BA, Kitahara K, Debnath A, Okamoto K, Miyoshi S-I. Accuracy of cholera rapid

diagnostic tests: a systematic review and meta-analysis. Clinical Microbiology and Infection

2021; 0. Available at: https://www.clinicalmicrobiologyandinfection.com/article/S1198-

743X(21)00489-4/fulltext. Accessed 2 November 2021.

16.   Ontweka LN, Deng LO, Rauzier J, et al. Cholera rapid test with enrichment step has

diagnostic performance equivalent to culture. PLOS ONE **2016**; 11:e0168257.

17.   Global Task Force on Cholera Control (GTFCC) Surveillance Working Group. Interim

guidance document on cholera surveillance. 2017; Available at: https://www.gtfcc.org/wp-

content/uploads/2019/10/gtfcc-interim-guidance-document-on-cholera-surveillance.pdf.

Accessed 30 September 2022.

18.   Weill F-X, Domman D, Njamkepo E, et al. Genomic history of the seventh pandemic of

cholera in Africa. Science **2017**; 358:785–789.

19.   Wang C, Lin X, Nelson KP. Bayesian hierarchical latent class models for estimating

diagnostic accuracy. Stat Methods Med Res **2020**; 29:1112–1128.

20.   Plummer M, Stukalov A, Denwood M. rjags: Bayesian graphical models using MCMC.

2022; Available at: https://CRAN.R-project.org/package=rjags. Accessed 17 August 2022.

21.   R Core Team. R: A language and environment for statistical computing. R Foundation for

Statistical Computing, Vienna, Austria. http://wwwR-project.org/ **2016**; Available at:

https://cir.nii.ac.jp/crid/1574231874043578752. Accessed 17 August 2022.

22.   Debes AK, Murt KN, Waswa E, et al. Laboratory and field evaluation of the Crystal VC-O1

cholera rapid diagnostic test. The American Journal of Tropical Medicine and Hygiene

2021; 104:2017–2023.

23.   Mwaba J, Ferreras E, Chizema-Kawesa E, et al. Evaluation of the SD bioline cholera rapid
diagnostic test during the 2016 cholera outbreak in Lusaka, Zambia. Tropical Medicine &
International Health **2018**; 23:834–840.

24.   Sayeed MA, Islam K, Hossain M, et al. Development of a new dipstick (Cholkit) for rapid
detection of Vibrio cholerae O1 in acute watery diarrheal stools. PLOS Neglected Tropical
Diseases **2018**; 12:e0006286.

25.   Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med **2002**;
21:1539–1558.

26.   Gronau QF, Heck DW, Berkhout SW, Haaf JM, Wagenmakers E-J. A primer on Bayesian
model-averaged meta-analysis. Advances in Methods and Practices in Psychological
Science **2021**; 4:25152459211031256.

27.   Viechtbauer W. I2 for multilevel and multivariate models. 2022. Available at:
https://www.metafor-project.org/doku.php/tips:i2_multilevel_multivariate. Accessed 26
August 2022.

28.   Zgheir SM, Mustafa NM, Ali AA, Al-Diwan J. Cholera Outbreak in Iraq, 2017. Ind Jour of
Publ Health Rese & Develop **2019**; 10:686.

29.   Chowdhury F, Khan IA, Patel S, et al. Diarrheal illness and healthcare seeking behavior
among a population at high risk for diarrhea in Dhaka, Bangladesh. PLOS ONE **2015**;
10:e0130105.

30.   Fissehaye T, Damte A, Fantahun A, Gebrekirstos K. Health care seeking behaviour of
mothers towards diarrheal disease of children less than 5 years in Mekelle city, North
Ethiopia. BMC Res Notes **2018**; 11:749.

31. Luquero FJ, Rondy M, Boncy J, et al. Mortality rates during cholera epidemic, Haiti, 2010–

2011. Emerging Infectious Diseases **2016**; 22. Available at:

https://wwwnc.cdc.gov/eid/article/22/3/14-1970_article. Accessed 9 September 2022.

32. McCrickard LS, Massay AE, Narra R, et al. Cholera mortality during urban epidemic, Dar

es Salaam, Tanzania, August 16, 2015–January 16, 2016. Emerging Infectious Diseases

2017; 23. Available at: https://wwwnc.cdc.gov/eid/article/23/13/17-0529_article. Accessed

9 September 2022.

Tables

Table 1. Study characteristics

Number of study-observations included in the dataset with each study characteristic. An individual study

has >1 study-observations if it reports *V. cholerae* positivity for >1 sampling method or country.

Category	Characteristic	Number of studies	Percent of studies
Study design	Surveillance	96	76.8
	Diagnostic test accuracy	19	15.2
	Vaccine effectiveness	9	7.2
	Other	1	0.8
Sampling method quality	High	37	29.6
	Low	88	70.4
Percent of suspected cases tested	0-4	15	12.0
	5-49	31	24.8
	50-95	22	17.6
	≥95	57	45.6
Number of tests used (of culture, PCR, and/or RDT)	1	98	78.4
	2	20	16.0
	≥3	7	5.6
Number of suspected cases tested	1-9[†]	1	0.8
	10-99	37	29.6
	100-999	62	49.6
	≥1000	25	20.0

435 [†]One multi-country surveillance study overall tested ≥10 suspected cholera cases for

436 *V. cholerae* O1/O139 but reported fewer than 10 tested in one country.

Figure legends

Figure 1. PRISMA flow diagram

Diagram illustrating literature selection process, including databases searched, literature screened, and full texts reviewed for eligibility. Reasons for exclusion are indicated along with the number of studies that fell within each category.

Figure 2. *Vibrio cholerae* positivity by study methodology and outbreak context

Proportion of suspected cholera cases that were confirmed positive by **A)** diagnostic test type, **B)** quality of sampling methods, where "high" includes all suspected cases or a random or stratified sample and "low" includes convenience or unreported sampling methods, **C)** age minimum in suspected case definition, where "0" indicates that no minimum age was set, and **D)** whether surveillance was initiated in response to an outbreak or whether it was routine surveillance or non-outbreak. Each point is a study-observation; individual studies may have multiple points if they reported positivity by multiple tests, reported results for multiple countries or outbreak contexts, and/or multiple sampling methods. Circles represent study-observations with high quality sampling and triangles indicate low quality sampling.

Figure 3. Estimated underlying *V. cholerae* positivity

A) Posterior distributions of pooled percent sensitivity and specificity of culture (top), PCR (middle), and RDT (bottom) for detecting *V. cholerae* O1/O139 infections in suspected cholera cases. Dashed lines represent median values of each distribution. **B)** "Unadjusted" is mean percent positive (95% confidence interval) from random effects meta-analysis implemented using R package ᴍᴇᴛᴀ without any adjustments. "Adjusted" is the underlying true percent positive (95% credible interval) estimated using the Bayesian hierarchical model, adjusted for sensitivity/specificity of the tests, minimum age in case definition, sampling quality, and whether surveillance was initiated in response to an outbreak.

Figure 4. Forest plot of study estimates and underlying positivity

Black points indicate median study-level underlying positivity and 95% Credible Interval (CI).

Teal, orange, and purple points indicate the proportion positive reported by study for culture,

PCR, and RDT, respectively, and corresponding error bars indicate 95% confidence interval for

a binomial probability. Studies are labeled by country ISO3 code, whether they used high quality

sampling methods, and whether a minimum age was set in the suspected cholera case

definition. Green distribution indicates median and 95% CI of pooled positivity. Pink distribution

indicates median and 95% CI of posterior predictive distribution of positivity. Studies are split

into outbreak and non-outbreak for ease of interpretation, but the green and pink distributions

represent the global estimates across all studies.